HALIFAX, NOVA SCOTIA — Immunovaccine Inc. announced Dec. 9 that its Investigational New Drug (IND) application for its therapeutic cancer vaccine, DPX-0907, has been cleared by the U.S. Food and Drug Administration.
DPX-0907 is Immunovaccine's lead therapeutic vaccine candidate. The vaccine uses the DepoVax platform to deliver tumor-specific antigens. DPX-0907 has the potential to stimulate the body's immune system to seek out and destroy cancer cells in patients with breast, ovarian and prostate cancer.
"The successful FDA review of our IND submission confirms our confidence in our regulatory and development strategy," said Dr. Randal Chase, Immunovaccine's president and CEO. "DPX-0907 is an appealing vaccine candidate to advance into human clinical trials because it combines the strength of our DepoVax™ platform with cancer signature antigens."
The Phase 1 clinical trial for DPX-0907 will be conducted at five sites in the United States and is on track to begin enrolling patients with breast, ovarian and prostate cancers by the end of April. The Phase 1 clinical trial will evaluate the safety and tolerability of Immunovaccine's DepoVax delivery system and seven tumor-associated antigens.